Download

Full Text

• Reimund JM, Wittersheim C, Dumont S, et al.- Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut, 1996, 39, 684-689.
• Munkholm P, Langholz E, Davidsen M, Binder V.- Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol, 1995, 30, 699-706.
• Hoie O, Wolters FL, Riis L, et al.- Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology, 2007, 132, 507-515.
• Van den Brande JM, Braat H, van den Brink GR, et al.- Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology, 2003, 124, 1774-1785.
• Shen C, Van Assche GV, Colpaert S, et al.- Adalimumab induces apoptosis of human monocytes : a comparative study with infliximab and etanercept. Aliment Pharmacol Ther, 2005, 21, 251-258.
• Sandborn WJ, Hanauer SB, Katz S, et al.- Etanercept for active Crohn's disease: a randomized, double-blind, placebo- controlled trial. Gastroenterology, 2001, 121, 1088-1094. (Pubitemid 33022088)
• Hanauer SB, Feagan BG, Lichtenstein GR, et al.- ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet, 2002, 359, 1541-1549.
• Sands BE, Anderson FH, Bernstein CN, et al.- Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med, 2004, 350, 876-885. (Pubitemid 38252535)
• Hanauer SB, Wagner CL, Bala M, et al.- Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol, 2004, 2, 542-553.
• Lichtenstein GR, Feagan BG, Cohen RD, et al.- Serious infections and mortality in association with therapies for Crohn's disease : TREAT registry. Clin Gastroenterol Hepatol, 2006, 4, 621-630.
• Rutgeerts P, Sandborn WJ, Feagan BG, et al.- Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med, 2005, 353, 2462-2476. (Pubitemid 41770166)
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al.- Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology, 2006, 130, 323-333.
• Sandborn WJ, Rutgeerts P, Enns R, et al.- Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med, 2007, 146, 829-838.
• Sandborn WJ, Feagan BG, Stoinov S, et al.- PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med, 2007, 357, 228-238.
• Sandborn WJ, Colombel JF, Enns R, et al.- Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med, 2005, 353, 1912-1925. (Pubitemid 41565956)
• Van Assche G, Van Ranst M, Sciot R, et al.- Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med, 2005, 353, 362-368. (Pubitemid 41132340)
• Feagan BG, Greenberg GR, Wild G, et al.- Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med, 2005, 352, 2499-2507. (Pubitemid 41007865)
• Mannon PJ, Fuss IJ, Mayer L, et al.- Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med, 2004, 351, 2069-2079. (Pubitemid 39482500)
• Sandborn WJ, Feagan BG, Fedorak RN, et al.- A randomized trial of ustékinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology, 2008, 135, 1130-1141.
• Plevy S, Salzberg B, Van Assche G, et al.- A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology, 2007, 133, 1414-1422. (Pubitemid 350029746)
• Ito H, Takazoe M, Fukuda Y, et al.- A randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology, 2004, 126, 989-996.
• Fedorak RN, Gangl A, Elson CO, et al.- Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology, 2000, 119, 1473-1482.
• Sinha A, Nightingale J, West KP, et al.- Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med, 2003, 349, 350-357. (Pubitemid 36886241)
• Sinha A, Nightingale J, West KP, et al.- Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med, 2003, 349, 350-357. (Pubitemid 36886241)